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Abstract
Breast cancer cell-response to inflammatory cytokines such as interleukin-6 (IL-6) and oncostatinM (OSM)may affect the
course of clinical disease in a cancer subtype-dependent manner. Furthermore, vascular endothelial growth factor A
(VEGF) secretion induced by IL-6 andOSMmay also be subtype-dependent. Utilizing datasets fromOncomine,we show
that poor survival of invasive ductal carcinoma (IDC) breast cancer patients is correlated with both high VEGF expression
and high cytokine or cytokine receptor expression in tumors. Importantly, epidermal growth factor receptor-negative
(HER2-), but notHER2-positive (HER2+), patient survival is significantly lowerwith high tumor co-expression of VEGF and
OSM, OSMRβ, IL-6, or IL-6Rα compared to low co-expression. Furthermore, assessment of HER2- breast cancer cells in
vitro identified unique signaling differences regulating cytokine-induced VEGF secretion. The levels of VEGF secretion
were analyzed by ELISA with siRNAs for hypoxia inducible factor 1 α (HIF1α) and signal transducer and activator of
transcription 3 (STAT3). Specifically, we found that estrogen receptor-negative (ER-) MDA-MB-231 cells respond only to
OSM through STAT3 signaling, while ER+ T47D cells respond to both OSM and IL-6, though to IL-6 to a lesser extent.
Additionally, in the ER+T47D cells, OSMsignals through both STAT3 andHIF1α. These results highlight that the survival
of breast cancer patients with high co-expression of VEGF and IL-6 family cytokines is dependent on breast cancer
subtype. Thus, the heterogeneity of human breast cancer in relation to IL-6 family cytokines and VEGF may have
important implications in clinical treatment options, disease progression, and ultimately patient prognosis.
Translational Oncology (2019) 12, 245–255
Introduction
In the United States, breast cancer is the most frequently diagnosed
cancer among women [1]. With 268,670 new cases of invasive breast
cancer (IBC) expected for 2018, breast cancer remains a leading
public health concern, both in the United States and globally. One of
the main concerns is the complex relationship between IBC subtypes,
clinical treatment, and long-term survival [1,2]. In particular, anti-
angiogenic treatments for breast cancer have had variable clinical
success at best, and at worst, show no improvement in disease-free
survival [3]. The high level of clinical variability with anti-angiogenic
therapies may be due, in part, to the highly heterogeneous nature
of breast cancer and their subsequent biomarkers [4]. This underlies
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the need to improve our understanding of clinical outcomes in
conjunction with existing breast cancer subtype biomarkers such as
estrogen receptor (ER), progesterone receptor (PR), and epidermal
growth factor 2 (HER2).
Current breast cancer subtype classifications depend on the
evaluation of ER, PR, and HER2 [5]. The luminal A (ER+ PR+
HER2-; low Ki67) breast cancer subtype is the least aggressive, while
the luminal B (ER+ PR+ HER2-; high Ki67 or HER2+) breast cancer
subtype is more aggressive and has an overall poorer prognosis [5–7].
In contrast, cancers classified as basal-like triple negative breast
cancer (TNBC; ER- PR- HER2-) are highly aggressive with increased
probability of relapse and display unfavorable prognoses, in large part
due to the lack of targeted therapies available to treat this subtype
[4,8]. Similarly, HER2-type breast cancers (ER- PR- HER2+) also
have poor prognoses [9]. While superficial differences between the
subtypes are relatively well known, the specific molecular mechanisms
that drive these differences remain elusive. Specifically, increased
inflammatory markers in the serum of breast cancer patients appear to
be associated with poor prognosis [10].
Inflammatory cytokines of the interleukin-6 (IL-6) family,
including IL-6 and oncostatin M (OSM), have been implicated in
the migration and invasiveness of human breast cancer cells [11–13],
while leukemia inhibitory factor (LIF) has been shown to act as a
tumor/metastasis suppressor [14–17]. Moreover, both IL-6 and OSM
have been shown to be capable of directly and indirectly driving
angiogenesis [18–20]. Receptor complexes of the IL-6 family all
consist of at least one molecule of glycoprotein 130 (gp130), as well
as subunit(s) specific to their respective receptor [21,22]. Following
IL-6 or OSM ligand binding, the gp130 receptor complexes
activate the JAK/STAT, MAPK, PI3K/AKT, and JNK pathways,
thereby mediating transcription of target genes [22–27]. Although IL-6
and LIF bind specifically to their individual receptors (IL-6R and LIFR,
respectively), OSM is capable of binding to both the LIFR and
the OSM receptor (OSMR), which it binds to with higher affinity
[28–30]. The resultant cytokine signaling cascades play various roles
in the progression of breast cancer through activation of target
genes involved in differentiation, survival, apoptosis, and angiogenesis
[26,31,32].
Normal angiogenesis is maintained in homeostasis by numerous pro-
and anti-angiogenic factors, resulting in a normal rate of blood vessel
growth [33]. During tumor angiogenesis, both tumor cells and tumor-
associated stromal/immune cells secrete proangiogenic factors [27,34].
The most potent proangiogenic factor, vascular endothelial growth factor
A (VEGF), promotes the survival, proliferation, and motility of
endothelial cells and enhances vascular permeability [35,36]. Regulation
of VEGF expression typically depends on hypoxia-driven signaling
through the binding of the dimeric transcription factor hypoxia-inducible
factor 1 (HIF1) [HIF1α + HIF1β] to the hypoxia response element
(HRE) in theVEGFpromoter. [37].However, activation of transcription
factor binding to sites other than the HRE, such as those for signal
transducer and activator of transcription-3 (STAT3), allow transcription
to be activated independently of hypoxia [38–41]. While it has been
shown that hypoxia can induce STAT3 phosphorylation [42,43],
hypoxia-induced pSTAT3 is not rapid. Therefore, cellular hypoxia likely
promotes the secretion of cytokines from breast tumor cells that then
promote STAT3 phosphorylation. In fact, hypoxia has been shown to
increase production of cytokines such as IL-6, IL-1α, and IL-1β, which
are all known to activate STAT3 signaling [44,45]. Even under non-
hypoxic conditions, IL-6 family cytokines have been shown to promote
VEGF expression via activation of transcription factors HIF1α and
STAT3 [19,27,46,47].
In this paper, we study the differential effects of the inflammatory
interleukin-6 (IL-6)-family cytokines on breast cancer patient outcomes,
as well as the induction of vascular endothelial growth factor A (VEGF) in
a breast cancer subtype-specific manner. Using collated Oncomine data,
we systemically explored the co-expression of VEGF with inflammatory
cytokine components among invasive ductal carcinoma (IDC) patients
subdivided by HER2- or HER2+ status. Importantly, we found that
HER2- patient survival significantly decreases when breast tumors co-
express high levels of VEGF and high levels of OSM, OSMRβ, IL-6, or
IL-6Rα. Conversely, in patients with HER2+ disease, co-expression of
VEGF and these inflammatory proteins had little to no effect on survival.
We also show that regulation of IL-6-family cytokine-induced VEGF in
HER2- cells differ between ER+ and ER- breast cancer cells. This study
highlights the breast cancer subtype-specific differences in cytokine
signaling that lead to VEGF secretion, and importantly, the potential for
therapeutic suppression of IL-6 family cytokines in HER2- breast cancer.
Materials and Methods
Oncomine Analysis
We utilized the Curtis Breast human mRNA microarray dataset from
Oncomine (Compendia Bioscience, AnnArbor,MI) to assess correlations
between inflammatory cytokines and VEGF. The constraints used to
define the dataset used were “Invasive Ductal Carcinoma” and a detailed
survival status of either “Alive” or “Dead ofDisease.”The resultant dataset
was used to calculate quartiles. From these, the upper quartile (N75th
percentile) and lower quartile (b25th percentile) were selected for
comparison in order to clearly depict survival trends that may have been
otherwise muddled by use of all quartile combinations. For co-expression
analysis, we calculated survival curves using patients in the upper quartile
of both VEGF and each particular IL-6 family gene (“high/high”) and
the lower quartile of both (“low/low”). Statistical analyses between
survival of two groups was calculated using a log-rank test in GraphPad
Prism 5 software *P b .05, **P b .01, ***P b .001.
Tissue Culture
Triple negative MDA-MB-231, luminal A T47D, and triple positive
BT474 human breast cancer cells (ATCC) were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS), 1%
penicillin streptomycin, and 1% sodium pyruvate and incubated at 37 °C
at 5% CO2. HER2+ SK-BR-3 human breast cancer cells were grown in
McCoy's 5A medium, while MDA-MB-453 human breast cancer cells
were grown in DMEM with the same supplements as above. Cytokine
treatments, in low serum media (1% FBS) at 25 ng/mL, included
recombinant human OSM (Cat#300-10 T, Peprotech), IL-6 (Cat
#200–06, Peprotech), and LIF (Cat# 300–05, Peprotech) for the
indicated time points.
siRNA Transfection
siRNA pools targeting HIF1α, STAT3, JNK1, and JNK2 were
obtained fromDharmacon. In brief, 300,000 cells/well were plated in a
6-well plate, and siRNAs were transfected according to the Fast-Forward
protocol as outlined by the manufacturer of Hyperfect siRNA
Transfection Reagent (Cat# 301705, Qiagen). STAT3 siRNAs were
used at 25 nM, and cells were transfected for 72 hours and then treated
with OSM for 48 hours. HIF1α, JNK1, and JNK2 siRNAs were used at
concentrations of 20 nM, and were transfected for 24 hours prior toOSM
treatment. Knockdown was assessed via immunoblot analysis (see below).
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Immunoblot Analysis
Cells were lysed on ice with 1x RIPA buffer containing 1x protease
inhibitor cocktail (Cat# P8340, Sigma Aldrich). Lysates were run on
an SDS-PAGE gel, transferred onto a nitrocellulose membrane, and
blocked overnight in 5% non-fat dry milk in PBS containing 0.05%
Tween 20. Membranes were incubated overnight with primary
antibodies forHIF1α (Dilution: 1:1000Cat# AF1935, R&DSystems),
STAT3 (Cat# 9132), p-STAT3 (Cat# 9145), JNK1 (Cat# 3708),
p-JNK1 (Cat# 4668), or β-Actin (Cat# 3700) ((1:1000, Cell Signaling
Technologies) in 5% NFDM-PBST. Membranes were washed with
PBST and incubated with HRP secondary antibody (Cat# 705–035-
003 Jackson ImmunoResearch) in 5% NFDM-PBST for 45 minutes,
developed with ECL, and imaged on X-ray film on a Kodak 4000R
Image Station.
VEGF ELISA
Analysis of VEGF secretion in the conditioned media (CM) of
MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and
BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via
VEGFELISA according to themanufacturer's protocol (Cat#Dy293B,
R&D Systems, Bethesda, MD). Cells were plated at a confluency of
50,000 or 100,000 cells in a 24-well plate and allowed to adhere
overnight. The following day, cells were serum-starved in serum free
media for 6 hours and treated with cytokines for the indicated time.
Figure 1. Inflammatory cytokine and VEGF co-expression are correlated with decreased survival of invasive ductal carcinoma patient.
These Kaplan–Meier curves in Figure 1, A and B, are a subset of the data presented in Supplemental Figure S1. A) Kaplan–Meier survival
curves of invasive ductal breast carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively) present
diminished survival when compared to individuals with low OSM and VEGF expression (lower quartiles, respectively). Comparable trends
appear upon examination of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C) IL-6 and VEGF expression,
and D) IL-6Rα and VEGF expression, indicating significant differences between upper and lower quartile survival for each group. Survival
of patients with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and VEGF expression are not significantly
different. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test *P b .05, **P b .01, ***P b .001.
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pSTAT3 ELISA
Intracellular pSTAT3 levels were assessed by ELISA, in accordance
with the manufacturer's protocol (Cat#7146, Cell Signaling). 50,000
cells were adhered to 24-well plates overnight in serum-free media.
Cells were incubated for the indicated times, and cell lysates were
collected using 1x Cell Lysis Buffer (Cat# 9803, Cell Signaling). The
lysates were diluted 1:3 with blocking buffer (PBS-0.05% Tween 20,
1% IgG-free BSA) and assessed by ELISA.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5
software. To compare multiple groups, one- or two-way analysis of
variance were run with Tukey's and Bonferroni's post-test,
respectively where appropriate on ELISA data. Experiments were
considered statistically significant if p values were less than 0.05. Error
bars represent mean ± S.E. Experiments were performed at least three
times to determine statistical significance.
Results
Inflammatory Cytokine and VEGF Co-Expression is Correlated
with Decreased Survival of IDC Patients
To address the clinical importance of IL-6 family cytokines in invasive
ductal carcinoma (IDC), we correlated patient survival relative to
expression levels of VEGF with OSM, IL-6, LIF, or their specific
receptor subunits. Using the Curtis METABRIC Breast dataset (47)
obtained from Oncomine [48], co-expression in IDC patients
was compared to survival and quantified by individual quartiles, as
demonstrated for OSM and VEGF (Figure S1A) and OSMRβ and
VEGF (Figure S1B). Utilizing just the upper and lower quartiles, we
observed a significant correlation between high co-expression of OSM
and VEGF and decreased survival, relative to low expression of both
OSM and VEGF (P = .0190, Figure 1A). Similarly, decreased survival
was observed in patients who had high expression levels of OSMRβ
and VEGF (P = .0012, Figure 1B), IL-6 and VEGF (P = .0005,
Figure 1C), or IL-6Rα and VEGF (P = .0016, Figure 1D) relative to
those with low co-expression of each respective gene pair. Patient
survival was not statistically affected by co-expression levels of LIF
and VEGF (P = .0578, Figure 1E) or LIFRβ and VEGF (P = .1020,
Figure 1F). Together, these results highlight the importance of tumor
cell co-expression of VEGF with OSM, OSMRβ, IL-6, or IL-6Rα on
the poor survival of individuals with IDC.
HER2- Status Dictates Poor Survival in IDC Patients with High
Co-Expression of OSM, IL-6, OSMRβ or IL-6Rα and VEGF
As published studies have demonstrated the importance of receptor
status in breast cancer recurrence and treatment [48–50], we next
analyzed HER2 status on the survival of IDC patients according to
VEGF and IL-6 familymolecule co-expression. A statistically significant
decrease in survival was only observed in HER2- patients with high
OSM and VEGF expression (P = .0016) and not in HER2+ patients
Figure 2. Co-expression of VEGF with OSM or OSMRβ appears to affect survival in HER2- but not HER2+ subtypes. A) Kaplan–Meier
survival curves of invasive ductal breast carcinoma for HER2- patients and HER2+ patients by OSM and VEGF expression. In HER2-
patients, high OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated with decreased survival when
compared to patients with low OSM and low VEGF expression (lower quartiles, respectively). However, this trend is not evident in HER2+
individuals, as no significant difference is observed between survival of patients with OSM and VEGF expression in upper and lower
quartiles, respectively. Similar trends are observed in Kaplan–Meier survival curves for B) HER2- and HER2+ by OSMRβ and VEGF
expression. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test *P b .05, **P b .01, ***P b .001.
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(P = .5963, Figure 2A). Decreased survival was also seen in HER2-
individuals with high OSMRβ and VEGF co-expression (P = .0001,
Figure 2B), high IL-6 and VEGF co-expression (P = .0005, Figure S2A),
and high IL-6Rα and VEGF co-expression (P = .0112; Figure S2B). No
statistically significant change in survival was detected with the respective
HER2+ individuals (High OSMRβ/VEGF, P = .9317, Figure 2B)
(High IL-6/VEGF, P = .6106, Figure S2A) (High IL-6Rα/VEGF,
P = .0671, Figure S2B). High expression of LIF with high expression of
VEGF also was correlated with poor survival in HER2- (P b .0001,
Figure S2C), but not HER2+ IDC patients (P = .2806 Figure S2C).
However, no association between HER2 status and survival was
observed in IDC patients expressing high levels of LIFRβ and VEGF
(P = .1247 and P = .534, respectively, Figure S2D). The effect of
estrogen receptor (ER) status on patient survival was also investigated.
Figure 3. IL-6 family cytokine OSM induces VEGF secretion independent of HIF1α signaling in MDA-MB-231 cells. A) Treatment with
OSM, IL-6, and LIF (25 ng/mL) for 24 hours promotes expression of HIF1α in MDA-MB-231 TNBC cells. Addition of an siRNA targeting
HIF1α (siHIF1α) ablates the effect of adding cytokines. B) T47D cells treated with IL-6 family cytokines for 72 hours express greater levels
of HIF1α relative to non-treated control. Treatment with siHIF1α reduces this effect, as assessed by immunoblot analysis. Immunoblots
are representative of at least 3 experiments. Induction of VEGF secretion is observed following treatment with IL-6 family cytokines
(25 ng/mL) for 24 hours in C) MDA-MB-231 cells (n = 5) and for 72 hours in D) T47D cells (n = 3), as determined by ELISA. Treatment with
siHIF1α does not affect VEGF secretion in OSM-treated MDA-MB-231 cells; however, VEGF secretion is modestly reduced in T47D cells
treated with OSM and siHIF1α. E) A panel of additional human breast cancer cell lines were tested for VEGF expression by ELISA. HER2-
MCF7 cells have significant OSM-induced VEGF secretion, while HER2+ BT474, SK-BR-3, and MDA-MB-453 cells do not produce
increased VEGF in response to OSM. One-way ANOVA, Tukey's post-test, **P b .01, ***P b .001.
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InHER2- IDCpatients, high co-expression ofOSM andVEGF inER+
patients was associated with poor survival (P = .0008), while ER- status
had no effect on survival (P = .6998, Figure S3A, B). ER status played a
less significant role in patient survival whenHER2 status was associated
high OSMRβ and VEGF co-expression (Figure S3, C and D). These
data suggest that while ER+ HER2- patients typically have fair
prognoses [51], high tumor co-expression of OSM and VEGF
negatively impacts survival in these individuals.
OSM Promotes VEGF Secretion from HER2- Breast Cancer
Cells in a HIF1α Differential Manner
Our data suggested that, high OSM co-expression with the
proangiogenic factor VEGF resulted in poor HER2- patient survival.
To study VEGF expression and its transcription factor, HIF1α, in
relation to IL-6 family cytokines, we used two distinct HER2- cell lines
with differing ER status, the ER-negative MDA-MB-231 (ER- PR-
HER2-) TNBC cell line and the ER-positive T47D (ER+ PR+ HER2-)
cell line.
Treatment with OSM, IL-6, or LIF (25 ng/mL) induced HIF1α
expression by western blot analysis in MDA-MB-231 cells at 24 hours
and in T47D cells at 72 hours, relative to non-treated cells (Figure 3, A
andB). These time points were selected as they were determined to have
maximal HIF1α-induction in each cell line (data not shown). Despite
the induction of HIF1α, treatment with IL-6 or LIF did not produce a
significant change in the level of VEGF secreted (Figure 3, C and D).
On the other hand, OSM treatment accounted for a 3-fold increase in
VEGF secretion by ELISA inMDA-MB-231 cells at 24 hours (P b .05)
and an almost 4-fold increase in T47D cells at 72 hours (P b .001)
(Figure 3, C andD). Relative VEGF secretion was not altered in MDA-
MB-231 cells treated with siHIF1α andOSM, while this same treatment
reduced VEGF secretion by nearly 50% in T47D cells, demonstrating
different signaling mechanisms. To confirm the importance of HER2-
status onOSM-inducedVEGF secretion, additional human breast cancer
cells were investigated. A 3.3-fold increase in VEGF secretion was seen
with ER+ HER2- MCF7 cells after a 72-hour treatment with OSM, as
compared to untreated controls (Figure 3E). Importantly, in HER2+
BT474 (ER+), SK-BR-3 (ER-), and MDA-MB-453 (ER-) cells [20,52],
OSMdid not induce VEGF secretion (Figure 3E), despite the presence of
OSMRβ in all cell lines (Figure S4A). Together, this data suggests that
OSM-induced VEGF induction is likely mediated through different
pathways in ER+ versus ER- HER2- cells.
To confirm a functional effect for OSM-induced VEGF production,
we performed in vitro and in vivo angiogenesis assays. Conditioned
media (CM) from MDA-MB-231 cells treated with OSM induced
endothelial cell tube and branch point formation in human umbilical
vein endothelial cells (Figure S5, A and B). Similarly, CM from OSM-
treated MDA-MB-231 cells had a 12-fold increase in angiogenesis, as
compared to CM from untreatedMDA-MB-231 cells whenmixed with
Matrigel and inserted into athymic nude mice (P b .001, Figure S5, C
andD). Together, these results suggest that OSMpromotes the secretion
of functional VEGF from breast cancer cells.
OSMStrongly Induces STAT3Activation in ER+ and ER-HER2-
Breast Cancer Cells
OSM is capable of binding to and activating both the OSMR and the
LIFR, while LIF binds to only the LIFR and IL-6 binds to the IL-6
receptor. Stimulation of these receptors activate various signaling
pathways including the STAT3 and JNK pathways [53–56]. First, we
Figure 4. OSM strongly induces phosphorylation of STAT3. A) Treatment with OSM (25 ng/mL) for 15 minutes, 30 minutes, and 1 hour
strongly induces phosphorylation of STAT3 (Tyr 705) in MDA-MB-231 cells and moderately induces JNK phosphorylation (T183/Y185).
Treatmentwith either IL-6 or LIF (25 ng/mL) does not induce pSTAT3 or pJNK. B) TreatmentwithOSM induces phosphorylation of STAT3 and
JNK in T47D cells. IL-6 induces moderate phosphorylation of STAT3 and JNK at early time points. Phosphorylation of STAT3 and JNK was
compared to control β-actin, as assessed by immunoblot analysis. Blots are representative of three experiments. Time course experiment for
STAT3 phosphorylation upon treatment with OSM or IL-6 (25 ng/mL) for 0.25–72 hours in C) MDA-MB-231 cells, and in D) T47D cells.
Treatment with IL-6 does not induce pSTAT3 expression in MDA-MB-231 cells, while inducing moderate pSTAT3 expression in T47D cells.
ELISA was performed in quadruplicate; two-way ANOVA with Bonferroni post-test, *P b .05, **P b .01, ***P b .001.
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confirmed that these receptor elements (OSMRβ, LIFRβ, IL-6Rα, and
gp130) were expressed in MDA-MB-231 and T47D cells by RT-PCR
(Figure S4B). Next, we sought to determine the mechanism by which
OSM induces the expression of VEGF by investigating the activation of
the transcription factors STAT3 and JNK, found downstreamofOSMR.
Treatment with OSM (25 ng/mL) strongly induced phosphorylation
of STAT3 (pSTAT3) in MDA-MB-231 TNBC cells at both 15 and
30 minutes, as assessed by immunoblot. In contrast, addition of OSM
only slightly induced phosphorylation of JNK1 (pJNK1) in these cells
(Figure 4A). Neither the addition of IL-6 nor LIF led to STAT3 or
JNK1 phosphorylation in ER- MDA-MB-231 cells. In T47D cells,
stimulation with either OSM or IL-6 promoted phosphorylation of
STAT3 at 15 and 30 minutes (Figure 4B). Phosphorylation of STAT3
was not induced in ER+T47D cells treated with LIF. A slight induction
of JNK1 phosphorylation was observed following treatment with OSM
in T47D cells, whereas IL-6 and LIF did not produce an effect. In both
cell lines, levels of OSM-induced STAT3 phosphorylation were
transient yet sustained over time up to 72 hours, with preferential
activation around 0.5 hours, relative to treatment with IL-6 (P b .001,
Figure 4, C and D). Interestingly, treatment with IL-6 has no observed
effect on pSTAT3 levels in MDA-MB-231 cells and only induced
moderate STAT3 phosphorylation in T47D cells.
Activation of STAT3 Signaling is Required for VEGF Secretion
by MDA-MB-231 TNBC Cells
Our data suggest thatOSM-induced VEGF is independent ofHIF1α in
MDA-MB-231 TNBC cells. To determine whether OSM promotes
VEGF secretion via the STAT3 pathway, we performed VEGF ELISAs
using siRNAs targeting STAT3 (siSTAT3) and JNK1 and 2 (siJNK1
and siJNK2). In MDA-MB-231 cells, treatment with OSM and
siSTAT3 suppressed VEGF secretion (Figure 5A). However, this
complete suppression was not observed in T47D cells, likely due to the
role of HIF1α in the secretion of VEGF in this cell line (Figure 5B).
While initial studies using a chemical inhibitor of JNK suggested
that JNK signaling was in part necessary for OSM-mediated induction
of VEGF (Figure S6A), further investigations revealed that these
effects might have resulted from the off-target suppression of STAT3
phosphorylation (Figure S6B). However, siRNAs targeting both
JNK1 and JNK2 (siJNK1 and siJNK2, respectively) had no effect on
the levels of VEGF secretion inMDA-MB-231 or T47D cells treated
with OSM (Figure 5, C and D). Together, these results demonstrate
that OSM-mediated induction of VEGF is dependent on STAT3 in
MDA-MB-231 cells, while T47D cells utilize STAT3, HIF1α, and
possibly other pathways to promote VEGF production in response
to OSM.
Figure 5. OSM induces VEGF via STAT3 signaling. A) Treatment with OSM (25 ng/mL) and siSTAT3 suppresses VEGF secretion by 3-fold
in MDA-MB-231 cells. B) Treatment with OSM and siSTAT3 moderately reduces VEGF secretion by T47D cells. VEGF secretion was not
reduced by the addition of siRNAs targeting both JNK1 and JNK2 in either C) MDA-MB-231 or D) T47D cells. Experiments were performed
in triplicate two-way ANOVA with Bonferroni post-test, *P b .05, ***P b .001.
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Discussion
The different subtype-specific molecular characteristics of human
breast cancer have important implications for clinical treatment
options, disease progression, and ultimately patient prognosis. In this
study, we show the correlation of high tumor cell co-expression of
VEGF with inflammatory cytokines (OSM and IL-6), or their
respective receptors (OSMRβ and IL-6Rα), with the poor survival of
individuals with HER2- invasive ductal carcinoma. This may be
caused by the fact that OSM, IL-6, and their receptors are associated
with increased metastatic capacity [57,58], including increased
invasion and migration [20,24,25,29,59] and the promotion of
angiogenesis [26,27,31,60]. Moreover, OSM has been shown to bind
to extracellular matrix proteins such as collagens, laminins, and
fibronectins in an active conformation; thereby, accumulating in a
breast tumor microenvironment to further promote these effects
[60,61]. Subsequently, we demonstrate that OSM induces VEGF in
HER2-, but not HER2+, breast cancer cells and that ER+ and ER-
HER2- tumor cells respond differently to IL-6 cytokines in their
induction of VEGF. Together, our findings suggest that VEGF, OSM,
and IL-6 or their receptors can be used as potential negative prognostic
markers and therapeutic targets for breast cancer.
Our clinical analysis for this work included 1245 IDC patients
subdivided by HER2 and ER status. When IDC patients were
subdivided by HER2 status, a marked decrease in overall survival was
found in HER2- patients exhibiting high OSM or OSMRβ and VEGF
co-expression compared to HER2+ patients. HER2- patients also fared
muchworse when their tumors had high co-expression of IL-6 or IL-6Rα
and VEGF. This data demonstrate clear statistical significance for breast
cancer patients with HER2-, but not HER2+ status. This was further
supported by our in vitro analyses showing that untreated HER2+
BT474 breast cancer cells constitutively express a basal level of VEGF
[62] and that OSM had no additional effect on the induction of VEGF
secretion inHER2+ cells such as BT474, SK-BR-3, andMDA-MB-453.
These findings may suggest redundancy between HER2 and inflamma-
tory cytokine-induced signaling, with most IDC tumors requiring
overactivation of only one or the other pathway. Other studies show that,
Figure 6. Mechanistically distinct regulation of VEGF secretion in MDA-MB-231 TNBC and T47D (ER+/PR+/HER2-) cells. A) The VEGF
promoter can be activated by various transcription factors. B) In MDA-MB-231 cells, OSM mediates VEGF secretion by activating the
STAT3 signaling pathway downstream of the OSMR (OSMRβ+ gp130). In T47D cells, OSM regulates VEGF secretion via both HIF1α and
the STAT3 signaling pathway.
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IL-6 family cytokines have been proposed as profilingmarkers forHER2-
breast cancer, specifically TNBC, while having no significant correlation
with HER2+ breast cancer [37]. Overall, these results indicate that the
inflammatory cytokines OSM and IL-6 contribute to the aggressive
phenotype seen with HER2- disease.
When investigating clinical IDC patient data with respect to ER
status, we were able to observe a significant negative effect on survival in
ER+/HER2- individuals with high co-expression of VEGF and OSM or
OSMRβ. This is interesting in light of the fact thatOSMhas been shown
to negatively regulate expression of the estrogen receptor itself [61]. Such
regulation may indicate a key element in OSM-driven malignancy, with
the possibility that ER+ tumor cells lose ER status over time and evolve to
become less susceptible to hormone therapies and more difficult to treat
[61]. Furthermore, several in vitro studies have demonstrated that OSM
has a greater effect inducing epithelial-mesenchymal transition (EMT)
and tumor cell detachment effects in ER+ PR+HER2- breast cancer cell
lines, such as T47D and MCF7, than on ER- TNBCs like MDA-MB-
231 or MDA-MB-468 ([27,63,64]; data not shown).
Standing alone, these results suggest important differences between
breast cancer subtypes in relation toVEGF and IL-6 family inflammatory
cytokines. As our patient data suggest that high coexpression of IL-6
family cytokines and VEGF levels leads to poor survival in HER2- breast
cancer, we investigated two HER2- breast cancer cell lines: ER- MDA-
MB-231 and ER+ T47D. In normal physiological conditions, VEGF
expression is regulated under both hypoxic and non-hypoxic conditions,
as the promoter region contains several response elements, including an
hypoxia response element (HRE) for HIF1, that allow for VEGF
regulation downstream of various signaling pathways (Figure 6A,
[38–41]). Our studies showed that OSM, IL-6, and LIF each increased
expression of HIF1α, an important transcription factor for VEGF,
but only OSM had a significant effect on VEGF production levels.
Additionally, there were key differences in the signaling pathways
inducingVEGF secretion. Specifically, we showed that T47D cells utilize
STAT3, HIF1α, and possibly other pathways, while MDA-MB-231
cells relied solely on STAT3 activation for OSM-induced VEGF
secretion. (Figure 6B). In T47D cells, it is possible that STAT3 and
HIF1α directly interact with each other to induce VEGF. Pawlus et al.
demonstrated that STAT3 and HIF1α immunoprecipitate together in
breast cancer cells and may have synergistic effects when both pathways
are activated [41]. Additionally, suppression ofHIF1 signaling byHIF1α
siRNA did not decrease hypoxia-induced STAT3 phosphorylation,
which suggests that STAT3 activation is not dependent on HIF1
signaling [65]. Together, these results may indicate unique properties
pertaining to angiogenic signaling in ER- TNBC versusER+ PR+HER2-
tumors.
Interestingly, although it might be expected that IL-6 should also
induce VEGF secretion from breast cancer cells, we found that in ER-
MDA-MB-231 cells, IL-6 did not activate the STAT3 pathway and
therefore did not promote VEGF secretion. Previous studies have
shown that IL-6 has no effect on some markers of metastatic fitness
such as E-cadherin levels in MDA-MB-231 cells, which are signaled
through the JAK/STAT3 pathway [66]. This suggests that while ER-
MDA-MB-231 cells express the IL-6 receptor, STAT3 signaling is
not necessarily regulated by IL-6 in these cells. While we showed that
IL-6 weakly activated the STAT3 pathway in ER+ T47D cells, this
induction was only seen in the first hour of treatment and did not
extend to 48 hours as did OSM-induced pSTAT3. Overall, the
activation of STAT3 signaling by OSM is significantly greater than
with IL-6 and highlights a difference in signaling magnitude and
possibly a key functional distinction between these two cytokines in a
breast cancer subtype-specific manner.
Taken together, our studies demonstrate that co-expression of VEGF
and IL-6 family cytokine molecules emerge as potential negative
prognostic markers particularly for HER2-, but not HER2+, invasive
ductal breast carcinoma. Our follow-up in vitro experiments demon-
strate distinct differential cytokine-induced STAT3 and HIF1α
signaling, which lead to varied levels of VEGF secretion among various
TNBC and ER+ PR+ HER2- breast tumor cells. These breast cancer
subtype-specific differences in HIF1α signaling could complicate anti-
cancer therapies targetingHIF1, which are currently undergoing clinical
trials [67]. Collectively, these results suggest that therapeutic inhibition
of IL-6-family cytokines such as OSM may lead to VEGF suppression
and improved patient survival in HER2- disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2018.10.004.
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